Answers are grounded in this paper and cite their sources.
The combination of sorafenib and bevacizumab has substantial toxicity and minimal efficacy in patients with previously treated metastatic breast cancer. Further study of this combination is not recommended.
No takes yet. Share an insight, caveat, or question.
Mina et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: